Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02464956 |
| Other study ID # |
DACL1011 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
December 2015 |
| Est. completion date |
February 2019 |
Study information
| Verified date |
September 2021 |
| Source |
Moorfields Eye Hospital NHS Foundation Trust |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
No treatments exist for Age-related Macular Degeneration (AMD) when there is cell loss such
as in late wet AMD or dry AMD. The differentiation of RPE cells from patient derived iPSC
will offer valuable source of tissue for transplantation in these forms of AMD and may form
basis for a future treatment option in terms of cell transplantation.
Description:
It has been shown that adult human skin cells or human blood cells can be reprogrammed to
become stem cells. This type of stem cell is called an induced Pluripotent Stem Cell
(iPSC).It has been shown specifically that this type of stem cell can be produced from adult
human skin cells or blood cells can in turn be converted into Retinal Pigment Epithelial
(RPE) cells. These RPE cells are a very important cell type in the human retina that are
abnormal and ultimately lost in Age-related Macular Degeneration (AMD). Although it has been
shown to be possible to make RPE cells from adult human skin, it has not been done to a level
to fulfil regulatory requirements for human transplantation in AMD.
This is a feasibility study involving 10 patients. The efficiency of creating an iPSC-Derived
RPE cells from a patient's own skin or blood will be examined. A sample size of 10 patients
will allow us to potentially consolidate the safety and efficacy of this method in order to
create these cells within the context of a future transplantation trial.
